- April 08, 2019 Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases
- March 29, 2019 Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis
- March 19, 2019 Spero Announces Appointment of Cynthia Smith to its Board of Directors
- March 14, 2019 Spero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review
- March 01, 2019 Spero Therapeutics to Present at March Investor Conferences
- February 26, 2019 Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720
- February 04, 2019 Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994
- January 29, 2019 Spero Therapeutics Announces Initiation of SPR720 Phase 1 Clinical Trial
- January 07, 2019 Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial
- January 07, 2019 Spero Therapeutics Announces Positive Feedback from FDA Pre-Phase 3 Meeting for Oral SPR994 and Submission of IND for SPR994 in cUTI
Displaying 1 - 10 of 78 results